II. Management: General Guidelines
- See Hypertension General Measures (includes DASH Diet)
- See Antihypertensive Selection
- See patients back at one month after starting agent
- Significantly improves compliance
- BP requires 1 month on agent to equilibrate
- Maximize compliance
- Work with patients to reduce adverse effects
- Switch to other agents if adverse effects significant
- Do not be overzealous
- Risk of overcorrection of Blood Pressure
- Avoid lowering diastolic pressure <70 mmHg
- Greater tolerance for elevated BP with increased age
- Study of 484 Swedish men over 70 from 1982-1992
- Risk if Diastolic Blood Pressure lowered below 90
- Increased cardiac event risk 3.9x
- Controlled for confounding factors
- Reference
- Consider nighttime dosing
- Advantages
- Variable data on cardiovascular events
- Studies showing decreased cardiovascular events and improve Blood Pressure control
- Studies showing no difference in cardiovascular outcomes compared with morning dosing
- Benefit may best in patients who do not dip their Blood Pressure overnight
- Non-dippers: Older, Diabetes Mellitus, Chronic Kidney Disease, Resistant Hypertension
- Consider 24 hour ambulatory monitoring to define unclear cases
- Variable data on cardiovascular events
- Disadvantages
- Risk of Orthostatic Hypotension and Fall Risk at night
- Risk of non-compliance
- Do not switch to nighttime dose if patient can not remember that dose
- The best time to dose is when the medication can be remembered (missed pills are useless)
- Indications to switch at least one medication to nighttime dosing
- Three or more Antihypertensives used
- Best medications for nighttime dosing
- References
- (2012) Prescr Lett 19(1): 4
- Hermida (2011) J Am Soc Nephrol 22: 2313-21 [PubMed]
- Advantages
III. Management: Choose Agents with Best Outcome Data
- See Antihypertensive Selection
- Medications that prevent Hypertension vascular sequelae
- Thiazide Diuretics
- ACE Inhibitors or Angiotensin Receptor Blockers (ARB)
- Long-acting Dihydropyridine Calcium Channel Blocker (e.g. Amlodipine)
- Beta-Blockers
- Indicated in patients with known Coronary Artery Disease or chronic, stable Systolic Dysfunction
- Not recommended as a first-line agent outside of specific cardiovascular indications
- Medications that prevent Left Ventricular Hypertrophy
- Most effective at reducing LVH risk
- ACE Inhibitors (e.g. Lisinopril) or Angiotensin Receptor Blockers (ARB)
- Diuretics (e.g. Chlorthalidone)
- Beta-Blockers (e.g. Metoprolol)
- Least effective at reduced LVH risk
- References
- Most effective at reducing LVH risk
IV. Management: Tailor Therapy to the Patient
- Assess patient risk factors and target Blood Pressures
- Management should include non-pharmacologic therapy for all patients
- Target medications to the patient
- Ongoing Blood Pressure Monitoring
- See Home Blood Pressure Monitoring
- Follow-up monthly until systolic Blood Pressure controlled (then every 3 to 6 months)
- Continue to review and encourage Nonpharmacologic Management of Hypertension
- Most patients require at least 2 medications for adequate Blood Pressure reduction to goal
- See Hypertension Combination Therapy
- Early combination therapy is most effective
- Lab monitoring
- Serum Creatinine and Electrolytes (e.g. chem8, basic metabolic panel) every 6 to 12 months
- Urine Microalbumin every 1 to 2 years (esp. for those not yet on an ACE Inhibitor or ARB)